Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Kymera Therapeutics (KYMR) Receivables - Net (2020 - 2025)

Kymera Therapeutics (KYMR) has disclosed Receivables - Net for 4 consecutive years, with $40.0 million as the latest value for Q2 2025.

  • On a quarterly basis, Receivables - Net changed N/A to $40.0 million in Q2 2025 year-over-year; TTM through Jun 2025 was $40.0 million, a N/A change, with the full-year FY2023 number at $15.0 million, changed N/A from a year prior.
  • Receivables - Net was $40.0 million for Q2 2025 at Kymera Therapeutics, up from $15.0 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $40.0 million in Q2 2025 to a low of $900000.0 in Q1 2021.
  • A 3-year average of $18.6 million and a median of $15.0 million in 2023 define the central range for Receivables - Net.